Back to top
more

Baxter International (BAX)

(Delayed Data from NYSE)

$35.87 USD

35.87
3,167,156

+0.17 (0.48%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $35.75 -0.12 (-0.33%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (74 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Compared to Estimates, Baxter (BAX) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

The headline numbers for Baxter (BAX) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Baxter International (BAX) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Baxter (BAX) delivered earnings and revenue surprises of 3.03% and 1.80%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

The Zacks Analyst Blog Baxter International, Henry Schein and IDEXX Laboratories

by Zacks Equity Research

Baxter International, Henry Schein and IDEXX Laboratories are included in this Analyst Blog.

Urmimala Biswas headshot

What's in Store for These 3 MedTech Stocks in Q2 Earnings?

by Urmimala Biswas

MedTech companies' quarterly results are likely to be strong on a sequential basis. Let's see how BAX, HSIC and IDXX are placed ahead of their earnings releases.

Exagen Inc. (XGN) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Exagen (XGN) delivered earnings and revenue surprises of 55.56% and 14.12%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Baxter (BAX) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Baxter's (BAX) second-quarter results are likely to benefit from positive pricing impact and new product launches. However, supply-chain issues are likely to have raised expenses in the quarter.

Perrigo (PRGO) Q2 Earnings Top Estimates

by Zacks Equity Research

Perrigo (PRGO) delivered earnings and revenue surprises of 10.42% and 5.79%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Countdown to Baxter (BAX) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS

by Zacks Equity Research

Get a deeper insight into the potential performance of Baxter (BAX) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Baxter's (BAX) Helion Surgical System Debuts in Thailand

by Zacks Equity Research

Baxter (BAX) launches the Helion Integrated Surgical System in Thailand, aiming to streamline operating room efficiency and enhance surgical team connectivity with cutting-edge technology.

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Baxter (BAX) Shares Rise 2.4% in July: Will It Go Higher?

by Zacks Equity Research

Shares of Baxter (BAX) are showing signs of stability after falling in the first half of 2024. Let's see what is driving investors' sentiment for the company.

Should Value Investors Buy Baxter International (BAX) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Carlyle Group (CG) Eyes Buyout of Baxter's Kidney Care Unit

by Zacks Equity Research

Carlyle Group (CG) is in talks to acquire Baxter's kidney care unit. The companies started exclusive negotiations in late June and an agreement could be announced as soon as this week.

Baxter (BAX) Recovers After Life2000 Ventilation Systems Recall

by Zacks Equity Research

Baxter (BAX) recalls Life2000 ventilators due to damaged battery charger dongles, posing a risk of device failure

Company News for July 8, 2024

by Zacks Equity Research

Companies In The News Article are: M, LI, BAX, CG and AMD.

Reasons to Retain Baxter International (BAX) in Your Portfolio Now

by Zacks Equity Research

Baxter International's (BAX) robust growth across all geographies, along with transformational initiatives, boosts confidence. However, pandemic-related disruption continues to hurt sales.

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why Baxter International (BAX) is a Strong Value Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Reasons to Retain Baxter International (BAX) in Your Portfolio Now

by Zacks Equity Research

Baxter International's (BAX) robust growth across all geographies, along with transformational initiatives, boosts confidence. However, pandemic-related disruption continues to hurt sales.

Why Baxter International (BAX) is a Top Value Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Baxter's (BAX) Clinolipid Gets FDA's Expanded Indication

by Zacks Equity Research

Baxter's (BAX) receipt of the latest expanded indication for Clinolipid is expected to meet the diverse nutritional needs of patients, ranging from preterm neonates to adults.

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Compared to Estimates, Baxter (BAX) Q1 Earnings: A Look at Key Metrics

by Zacks Equity Research

Although the revenue and EPS for Baxter (BAX) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Baxter (BAX) Q1 Earnings Beat Estimates, '24 EPS View Raised

by Zacks Equity Research

Baxter (BAX) reports better-than-expected first-quarter earnings and sales. BAX's quarterly results reflect solid demand for a range of its medically essential products.

Baxter International (BAX) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Baxter (BAX) delivered earnings and revenue surprises of 6.56% and 1.20%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?